Dupont Capital Management’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Dupont Capital Management’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-25,152	Closed	-$432K	–	1060
2018 Q1	$432K	Hold	25,152	–	–	0.01%	697
2017 Q4	$551K	Buy	25,152 +16,818	+202%	+$541K	0.01%	642
2017 Q3	$341K	Buy	+8,334	New	+$262K	0.01%	741
2017 Q1	–	Sell	-17,629	Closed	-$883K	–	910
2016 Q4	$883K	Hold	17,629	–	–	0.02%	529
2016 Q3	$925K	Buy	+17,629	New	+$842K	0.02%	469

Other funds holding FPRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Dupont Capital Management's FPRX Position: Q2 2018 in Review

Dupont Capital Management sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2018, closing a stake of 25,152 shares — an estimated $432K sold.

Dupont Capital Management first reported a position in FPRX in Q3 2016 and held it in 5 quarters. The position peaked at $925K in Q3 2016. 123 funds tracked by Wall St. Rank hold FPRX as of Q2 2018.

Dupont Capital Management reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2018 after selling out during the quarter.
Dupont Capital Management sold 25,152 Five Prime Therapeutics, Inc. shares in Q2 2018, an estimated $432K.
Dupont Capital Management first reported a position in Five Prime Therapeutics, Inc. in Q3 2016 and held it in 5 quarters.
Dupont Capital Management's Five Prime Therapeutics, Inc. position peaked at $925K in Q3 2016.
123 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2018.

Based on Dupont Capital Management's 13F filing for Q2 2018, filed 30 Jul 2018.